COVID-19 in multiple sclerosis: The Dutch experience
Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested pos...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2020-09, Vol.26 (10), p.1256-1260 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1260 |
|---|---|
| container_issue | 10 |
| container_start_page | 1256 |
| container_title | Multiple sclerosis |
| container_volume | 26 |
| creator | Loonstra, Floor C Hoitsma, Elske van Kempen, Zoé LE Killestein, Joep Mostert, Jop P |
| description | Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed. |
| doi_str_mv | 10.1177/1352458520942198 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7493197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458520942198</sage_id><sourcerecordid>2442589341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-774f3e0b026358aacad091091190bfdbfdc3bd6d8f477083114ef8c105c9d5913</originalsourceid><addsrcrecordid>eNp1UFtLwzAYDaK4OX33SQo-V3NtEh8E6bwMBnuZvoY0TbeOrq1JK_rvzdicFxA-SOCc75zzHQDOEbxCiPNrRBimTDAMJcVIigMwRJTzGEoOD8M_wPEGH4AT71cQQs4JOwYDgpMEc4qHgKazl8k4RjIq62jdV13ZVjbyprKu8aW_ieZLG437ziwj-95aV9ra2FNwVOjK27PdOwLPD_fz9Cmezh4n6d00NgyLLuacFsTCDOKEMKG10TmUKAySMCvyMIZkeZKLImSGgiBEbSEMgszInElERuB2q9v22drmxtad05VqXbnW7kM1ulS_kbpcqkXzpjiVBEkeBC53Aq557a3v1KrpXR0yK0wpZkISurGBW5YJN3tni70DgmrTs_rbc1i5-Jlsv_BVbCDEW4LXC_vt-q_gJ-TPg54</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442589341</pqid></control><display><type>article</type><title>COVID-19 in multiple sclerosis: The Dutch experience</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Loonstra, Floor C ; Hoitsma, Elske ; van Kempen, Zoé LE ; Killestein, Joep ; Mostert, Jop P</creator><creatorcontrib>Loonstra, Floor C ; Hoitsma, Elske ; van Kempen, Zoé LE ; Killestein, Joep ; Mostert, Jop P</creatorcontrib><description>Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458520942198</identifier><identifier>PMID: 32662742</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Betacoronavirus ; Cell number ; Coronavirus Infections - blood ; Coronavirus Infections - epidemiology ; Coronavirus Infections - mortality ; Coronavirus Infections - physiopathology ; Coronaviruses ; COVID-19 ; Female ; Hospitalization - statistics & numerical data ; Humans ; Immunologic Factors - therapeutic use ; Intensive Care Units ; Lymphocyte Count ; Lymphocytes ; Lymphopenia - blood ; Lymphopenia - epidemiology ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - epidemiology ; Netherlands - epidemiology ; Pandemics ; Pneumonia, Viral - blood ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - mortality ; Pneumonia, Viral - physiopathology ; SARS-CoV-2 ; Severity of Illness Index ; Short Report ; Young Adult</subject><ispartof>Multiple sclerosis, 2020-09, Vol.26 (10), p.1256-1260</ispartof><rights>The Author(s), 2020</rights><rights>The Author(s), 2020 2020 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-774f3e0b026358aacad091091190bfdbfdc3bd6d8f477083114ef8c105c9d5913</citedby><cites>FETCH-LOGICAL-c528t-774f3e0b026358aacad091091190bfdbfdc3bd6d8f477083114ef8c105c9d5913</cites><orcidid>0000-0002-1644-4410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458520942198$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458520942198$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,21818,27923,27924,43620,43621</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32662742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loonstra, Floor C</creatorcontrib><creatorcontrib>Hoitsma, Elske</creatorcontrib><creatorcontrib>van Kempen, Zoé LE</creatorcontrib><creatorcontrib>Killestein, Joep</creatorcontrib><creatorcontrib>Mostert, Jop P</creatorcontrib><title>COVID-19 in multiple sclerosis: The Dutch experience</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed.</description><subject>Adult</subject><subject>Aged</subject><subject>Betacoronavirus</subject><subject>Cell number</subject><subject>Coronavirus Infections - blood</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - physiopathology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Female</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Intensive Care Units</subject><subject>Lymphocyte Count</subject><subject>Lymphocytes</subject><subject>Lymphopenia - blood</subject><subject>Lymphopenia - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Netherlands - epidemiology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - blood</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>SARS-CoV-2</subject><subject>Severity of Illness Index</subject><subject>Short Report</subject><subject>Young Adult</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1UFtLwzAYDaK4OX33SQo-V3NtEh8E6bwMBnuZvoY0TbeOrq1JK_rvzdicFxA-SOCc75zzHQDOEbxCiPNrRBimTDAMJcVIigMwRJTzGEoOD8M_wPEGH4AT71cQQs4JOwYDgpMEc4qHgKazl8k4RjIq62jdV13ZVjbyprKu8aW_ieZLG437ziwj-95aV9ra2FNwVOjK27PdOwLPD_fz9Cmezh4n6d00NgyLLuacFsTCDOKEMKG10TmUKAySMCvyMIZkeZKLImSGgiBEbSEMgszInElERuB2q9v22drmxtad05VqXbnW7kM1ulS_kbpcqkXzpjiVBEkeBC53Aq557a3v1KrpXR0yK0wpZkISurGBW5YJN3tni70DgmrTs_rbc1i5-Jlsv_BVbCDEW4LXC_vt-q_gJ-TPg54</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Loonstra, Floor C</creator><creator>Hoitsma, Elske</creator><creator>van Kempen, Zoé LE</creator><creator>Killestein, Joep</creator><creator>Mostert, Jop P</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1644-4410</orcidid></search><sort><creationdate>20200901</creationdate><title>COVID-19 in multiple sclerosis: The Dutch experience</title><author>Loonstra, Floor C ; Hoitsma, Elske ; van Kempen, Zoé LE ; Killestein, Joep ; Mostert, Jop P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-774f3e0b026358aacad091091190bfdbfdc3bd6d8f477083114ef8c105c9d5913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Betacoronavirus</topic><topic>Cell number</topic><topic>Coronavirus Infections - blood</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - physiopathology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Female</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Intensive Care Units</topic><topic>Lymphocyte Count</topic><topic>Lymphocytes</topic><topic>Lymphopenia - blood</topic><topic>Lymphopenia - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Netherlands - epidemiology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - blood</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>SARS-CoV-2</topic><topic>Severity of Illness Index</topic><topic>Short Report</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loonstra, Floor C</creatorcontrib><creatorcontrib>Hoitsma, Elske</creatorcontrib><creatorcontrib>van Kempen, Zoé LE</creatorcontrib><creatorcontrib>Killestein, Joep</creatorcontrib><creatorcontrib>Mostert, Jop P</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loonstra, Floor C</au><au>Hoitsma, Elske</au><au>van Kempen, Zoé LE</au><au>Killestein, Joep</au><au>Mostert, Jop P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 in multiple sclerosis: The Dutch experience</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>26</volume><issue>10</issue><spage>1256</spage><epage>1260</epage><pages>1256-1260</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32662742</pmid><doi>10.1177/1352458520942198</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1644-4410</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2020-09, Vol.26 (10), p.1256-1260 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7493197 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Betacoronavirus Cell number Coronavirus Infections - blood Coronavirus Infections - epidemiology Coronavirus Infections - mortality Coronavirus Infections - physiopathology Coronaviruses COVID-19 Female Hospitalization - statistics & numerical data Humans Immunologic Factors - therapeutic use Intensive Care Units Lymphocyte Count Lymphocytes Lymphopenia - blood Lymphopenia - epidemiology Male Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Netherlands - epidemiology Pandemics Pneumonia, Viral - blood Pneumonia, Viral - epidemiology Pneumonia, Viral - mortality Pneumonia, Viral - physiopathology SARS-CoV-2 Severity of Illness Index Short Report Young Adult |
| title | COVID-19 in multiple sclerosis: The Dutch experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A27%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20in%20multiple%20sclerosis:%20The%20Dutch%20experience&rft.jtitle=Multiple%20sclerosis&rft.au=Loonstra,%20Floor%20C&rft.date=2020-09-01&rft.volume=26&rft.issue=10&rft.spage=1256&rft.epage=1260&rft.pages=1256-1260&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458520942198&rft_dat=%3Cproquest_pubme%3E2442589341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442589341&rft_id=info:pmid/32662742&rft_sage_id=10.1177_1352458520942198&rfr_iscdi=true |